{"id":17623,"date":"2020-01-29T10:13:02","date_gmt":"2020-01-29T09:13:02","guid":{"rendered":"https:\/\/www.satt.fr\/syndivia-receives-the-exclusive-license-from-satt-conectus-to-darx-technology\/"},"modified":"2020-01-29T17:05:22","modified_gmt":"2020-01-29T16:05:22","slug":"syndivia-receives-the-exclusive-license-from-satt-conectus-to-darx-technology","status":"publish","type":"post","link":"https:\/\/www.satt.fr\/en\/syndivia-receives-the-exclusive-license-from-satt-conectus-to-darx-technology\/","title":{"rendered":"Syndivia receives the exclusive license from SATT Conectus to DARx technology"},"content":{"rendered":"<p><strong>Syndivia receives the exclusive license from SATT Conectus to DARx technology, which allows them to generate monodisperse 1-to-1 conjugates starting from off the shelf protein substrates (e.g., therapeutic antibodies). Antibody-drug and antibody-oligonucleotide conjugates with a degree of conjugation of 1 (DAR1), obtained using DARx, were demonstrated to have improved therapeutic indexes due to improved PK\/PD parameters.<\/p>\n<p><\/strong><\/p>\n<p><span class=\"xn-location\">STRASBOURG, France<\/span>,\u00a0<span class=\"xn-chron\">Jan. 28, 2020<\/span>\u00a0\/PRNewswire\/ &#8212;\u00a0Syndivia, a biotechnology company focused on the development of new therapeutic modalities for solid cancers based on a specific targeting of the tumour microenvironment and anatomical hallmarks, announced today that it has been granted an exclusive, worldwide license by SATT Conectus for a technology (DARx) that opens access to a wide range of previously inaccessible biologics formats, such as antibody\u2013drug, antibody\u2013oligonucleotide, and antibody\u2013interleukin conjugates with a defined degree of conjugation of 1. This minimum possible degree of conjugation was found to have important advantages for addressing solid cancer indications\u00a0<i>in vivo<\/i>. The development of this technology for both therapeutic and diagnostics applications will be carried out by Syndivia in\u00a0<span class=\"xn-location\">Strasbourg, France<\/span>.<\/p>\n<p>Commenting on this news,<strong> Dr\u00a0<span class=\"xn-person\">Sasha Koniev<\/span>, Syndivia&#8217;s CEO,<\/strong> said, &#8220;<em>The unique feature of DARx is that it allows us to readily link in a straightforward way any off-the-shelf antibody with virtually any payload to generate 1-to-1 immunoconjugates. The results we have obtained to date in the ADC and AOC domains look very promising, namely in\u00a0in vivo\u00a0models of highly heterogenic solid tumours<\/em>.&#8221;<\/p>\n<p><strong><span class=\"xn-person\">Caroline Dreyer<\/span>, Conectus&#8217; CEO,<\/strong> shares that enthusiasm: &#8220;<em>Cutting-edge academic research has been the cornerstone of Syndivia&#8217;s success story thanks to the scientific excellence of the BioFunctional Chemistry (BFC) team at the CNRS\/Universit\u00e9 de\u00a0<span class=\"xn-location\">Strasbourg<\/span>\u00a0led by\u00a0<span class=\"xn-person\">Alain Wagner<\/span>\u00a0and with the support of Conectus. Today, Syndivia is expanding its capabilities with this new enabling technology. Conectus has once again demonstrated the relevance of its investment in the proof-of-concept of DARx technology, showcasing its broad application scope. After a first technology transfer at Syndivia&#8217;s inception, this new license also illustrates the virtuous circle of our collaborative co-conception model, whereby the BFC team, Syndivia, and Conectus work jointly and as a result can create economic and innovative momentum<\/em>.&#8221;<\/p>\n<p>Syndivia will undertake further development of the technology and the resulting drug candidates in exchange for undisclosed upfront and milestone payments to Conectus.<\/p>\n<p><strong><span style=\"font-size: 10pt;\">About DARx<\/span><\/strong><\/p>\n<p><span style=\"font-size: 10pt;\">DARx technology allows direct covalent linkage of payloads with off-the-shelf proteins, including antibodies, in a defined 1-to-1 manner, thus yielding bioconjugates with a defined degree of conjugation.<\/span><\/p>\n<p><strong><span style=\"font-size: 10pt;\">About SATT Conectus<\/span><\/strong><\/p>\n<p><span style=\"font-size: 10pt;\">SATT* Conectus Alsace is the main entry point for business partners and companies for accessing all the innovations and capabilities from public research in Alsace, one of the top-ranked territories for the excellence of research in France. It borders Germany and Switzerland at the intersection of the most innovative areas in Europe. Thanks to its investment fund (up to \u20ac500k per innovative project), SATT Conectus offers advanced applicative technologies whose proof of concept has been established and which are ready to industrialize. As a result, investors will have access to groundbreaking startups built around those breakthrough, yet matured, technologies. Another type of collaboration allows companies to co-develop high-potential innovative projects with public research, in order to tailor them to their specific needs.<\/span><\/p>\n<p><span style=\"font-size: 10pt;\">Since 2012: 1,046 collaborative research contracts signed; 102 innovative projects financed to a total of \u20ac31.7 M; 86 technologies transferred; 17 startups created; Over \u20ac100M raised from investors. Shareholders: CNRS, Inserm, ENGEES, INSA, Universit\u00e9 de Strasbourg, Universit\u00e9 de Haute Alsace, Bpifrance.<\/span><br \/>\n<span style=\"font-size: 10pt;\">www.conectus.fr\/en \u25cb http:\/\/conectlabs.conectus.fr\/en \u25cb @ConectusAlsace<\/span><br \/>\n<span style=\"font-size: 10pt;\">* Organization for accelerating tech transfer<\/span><\/p>\n<p><strong><span style=\"font-size: 10pt;\">About Syndivia<\/span><\/strong><\/p>\n<p><span style=\"font-size: 10pt;\">Syndivia is a research-driven biotechnology company that is developing a pipeline of targeted therapies for solid cancers by leveraging a unique microenvironment for and anatomical hallmarks of these tumours. Syndivia&#8217;s mission is to develop new therapies for patients with the most difficult cancer indications. For more information, visit https:\/\/www.syndivia.com.<\/p>\n<p>\n<\/span><\/p>\n<p><span style=\"font-size: 14pt;\"><strong>Media Contact<\/strong><\/span><\/p>\n<p>Syndivia<br \/>\nSasha Koniev \u2013 CEO<br \/>\nPhone: 00 33 3 67 10 42 20<br \/>\nEmail: enquiry@syndivia.com<\/p>\n<p><strong>\u00a0<\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Syndivia receives the exclusive license from SATT Conectus to DARx technology, which allows them to generate monodisperse 1-to-1 conjugates starting from off the shelf protein substrates (e.g., therapeutic antibodies). Antibody-drug and antibody-oligonucleotide conjugates with a degree of conjugation of 1 (DAR1), obtained using DARx, were demonstrated to have improved therapeutic indexes due to improved PK\/PD [&hellip;]<\/p>\n","protected":false},"author":7,"featured_media":17625,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[567,568,604],"tags":[],"class_list":["post-17623","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news-en","category-successstories-en","category-startup-en"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Syndivia receives the exclusive license from SATT Conectus to DARx technology - R\u00e9seau SATT<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.satt.fr\/en\/syndivia-receives-the-exclusive-license-from-satt-conectus-to-darx-technology\/\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"France MANDRY\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.satt.fr\/en\/syndivia-receives-the-exclusive-license-from-satt-conectus-to-darx-technology\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.satt.fr\/en\/syndivia-receives-the-exclusive-license-from-satt-conectus-to-darx-technology\/\"},\"author\":{\"name\":\"France MANDRY\",\"@id\":\"https:\/\/www.satt.fr\/en\/#\/schema\/person\/3c07a164c17f01f656480221ba81ab4e\"},\"headline\":\"Syndivia receives the exclusive license from SATT Conectus to DARx technology\",\"datePublished\":\"2020-01-29T09:13:02+00:00\",\"dateModified\":\"2020-01-29T16:05:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.satt.fr\/en\/syndivia-receives-the-exclusive-license-from-satt-conectus-to-darx-technology\/\"},\"wordCount\":663,\"image\":{\"@id\":\"https:\/\/www.satt.fr\/en\/syndivia-receives-the-exclusive-license-from-satt-conectus-to-darx-technology\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.satt.fr\/wp-content\/uploads\/2020\/01\/Syndivia.jpg\",\"articleSection\":[\"News\",\"Success Stories\",\"Start-up\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.satt.fr\/en\/syndivia-receives-the-exclusive-license-from-satt-conectus-to-darx-technology\/\",\"url\":\"https:\/\/www.satt.fr\/en\/syndivia-receives-the-exclusive-license-from-satt-conectus-to-darx-technology\/\",\"name\":\"Syndivia receives the exclusive license from SATT Conectus to DARx technology - R\u00e9seau SATT\",\"isPartOf\":{\"@id\":\"https:\/\/www.satt.fr\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.satt.fr\/en\/syndivia-receives-the-exclusive-license-from-satt-conectus-to-darx-technology\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.satt.fr\/en\/syndivia-receives-the-exclusive-license-from-satt-conectus-to-darx-technology\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.satt.fr\/wp-content\/uploads\/2020\/01\/Syndivia.jpg\",\"datePublished\":\"2020-01-29T09:13:02+00:00\",\"dateModified\":\"2020-01-29T16:05:22+00:00\",\"author\":{\"@id\":\"https:\/\/www.satt.fr\/en\/#\/schema\/person\/3c07a164c17f01f656480221ba81ab4e\"},\"breadcrumb\":{\"@id\":\"https:\/\/www.satt.fr\/en\/syndivia-receives-the-exclusive-license-from-satt-conectus-to-darx-technology\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.satt.fr\/en\/syndivia-receives-the-exclusive-license-from-satt-conectus-to-darx-technology\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.satt.fr\/en\/syndivia-receives-the-exclusive-license-from-satt-conectus-to-darx-technology\/#primaryimage\",\"url\":\"https:\/\/www.satt.fr\/wp-content\/uploads\/2020\/01\/Syndivia.jpg\",\"contentUrl\":\"https:\/\/www.satt.fr\/wp-content\/uploads\/2020\/01\/Syndivia.jpg\",\"width\":6399,\"height\":3569},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.satt.fr\/en\/syndivia-receives-the-exclusive-license-from-satt-conectus-to-darx-technology\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/www.satt.fr\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Syndivia receives the exclusive license from SATT Conectus to DARx technology\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.satt.fr\/en\/#website\",\"url\":\"https:\/\/www.satt.fr\/en\/\",\"name\":\"R\u00e9seau SATT\",\"description\":\"Les Soci\u00e9t\u00e9s d&#039;Acc\u00e9l\u00e9ration du Transfert de Technologies\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.satt.fr\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.satt.fr\/en\/#\/schema\/person\/3c07a164c17f01f656480221ba81ab4e\",\"name\":\"France MANDRY\",\"url\":\"https:\/\/www.satt.fr\/en\/author\/france\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Syndivia receives the exclusive license from SATT Conectus to DARx technology - R\u00e9seau SATT","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.satt.fr\/en\/syndivia-receives-the-exclusive-license-from-satt-conectus-to-darx-technology\/","twitter_misc":{"Written by":"France MANDRY","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.satt.fr\/en\/syndivia-receives-the-exclusive-license-from-satt-conectus-to-darx-technology\/#article","isPartOf":{"@id":"https:\/\/www.satt.fr\/en\/syndivia-receives-the-exclusive-license-from-satt-conectus-to-darx-technology\/"},"author":{"name":"France MANDRY","@id":"https:\/\/www.satt.fr\/en\/#\/schema\/person\/3c07a164c17f01f656480221ba81ab4e"},"headline":"Syndivia receives the exclusive license from SATT Conectus to DARx technology","datePublished":"2020-01-29T09:13:02+00:00","dateModified":"2020-01-29T16:05:22+00:00","mainEntityOfPage":{"@id":"https:\/\/www.satt.fr\/en\/syndivia-receives-the-exclusive-license-from-satt-conectus-to-darx-technology\/"},"wordCount":663,"image":{"@id":"https:\/\/www.satt.fr\/en\/syndivia-receives-the-exclusive-license-from-satt-conectus-to-darx-technology\/#primaryimage"},"thumbnailUrl":"https:\/\/www.satt.fr\/wp-content\/uploads\/2020\/01\/Syndivia.jpg","articleSection":["News","Success Stories","Start-up"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.satt.fr\/en\/syndivia-receives-the-exclusive-license-from-satt-conectus-to-darx-technology\/","url":"https:\/\/www.satt.fr\/en\/syndivia-receives-the-exclusive-license-from-satt-conectus-to-darx-technology\/","name":"Syndivia receives the exclusive license from SATT Conectus to DARx technology - R\u00e9seau SATT","isPartOf":{"@id":"https:\/\/www.satt.fr\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.satt.fr\/en\/syndivia-receives-the-exclusive-license-from-satt-conectus-to-darx-technology\/#primaryimage"},"image":{"@id":"https:\/\/www.satt.fr\/en\/syndivia-receives-the-exclusive-license-from-satt-conectus-to-darx-technology\/#primaryimage"},"thumbnailUrl":"https:\/\/www.satt.fr\/wp-content\/uploads\/2020\/01\/Syndivia.jpg","datePublished":"2020-01-29T09:13:02+00:00","dateModified":"2020-01-29T16:05:22+00:00","author":{"@id":"https:\/\/www.satt.fr\/en\/#\/schema\/person\/3c07a164c17f01f656480221ba81ab4e"},"breadcrumb":{"@id":"https:\/\/www.satt.fr\/en\/syndivia-receives-the-exclusive-license-from-satt-conectus-to-darx-technology\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.satt.fr\/en\/syndivia-receives-the-exclusive-license-from-satt-conectus-to-darx-technology\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.satt.fr\/en\/syndivia-receives-the-exclusive-license-from-satt-conectus-to-darx-technology\/#primaryimage","url":"https:\/\/www.satt.fr\/wp-content\/uploads\/2020\/01\/Syndivia.jpg","contentUrl":"https:\/\/www.satt.fr\/wp-content\/uploads\/2020\/01\/Syndivia.jpg","width":6399,"height":3569},{"@type":"BreadcrumbList","@id":"https:\/\/www.satt.fr\/en\/syndivia-receives-the-exclusive-license-from-satt-conectus-to-darx-technology\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.satt.fr\/en\/"},{"@type":"ListItem","position":2,"name":"Syndivia receives the exclusive license from SATT Conectus to DARx technology"}]},{"@type":"WebSite","@id":"https:\/\/www.satt.fr\/en\/#website","url":"https:\/\/www.satt.fr\/en\/","name":"R\u00e9seau SATT","description":"Les Soci\u00e9t\u00e9s d&#039;Acc\u00e9l\u00e9ration du Transfert de Technologies","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.satt.fr\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.satt.fr\/en\/#\/schema\/person\/3c07a164c17f01f656480221ba81ab4e","name":"France MANDRY","url":"https:\/\/www.satt.fr\/en\/author\/france\/"}]}},"_links":{"self":[{"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/posts\/17623","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/comments?post=17623"}],"version-history":[{"count":1,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/posts\/17623\/revisions"}],"predecessor-version":[{"id":17626,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/posts\/17623\/revisions\/17626"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/media\/17625"}],"wp:attachment":[{"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/media?parent=17623"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/categories?post=17623"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/tags?post=17623"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}